Fairvalue-Calculator Fairvalue-Calculator
EN DE

HBM Holdings (HBMHF) Fair Value & Analysis

Healthcare · US · Market cap $1.3B

Price$1.56
Fair Value$1.98
Upside+26.9%
Quality95/100
Evidence: High Range $1.48 – $2.44

Fair value as of: Jun 24, 2026

Analysis

HBM Holdings (HBMHF) currently trades at $1.56, while our model-based Fair Value estimate is $1.98 — implying the stock looks roughly 26.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is developing HBM7020 for treating hepatocellular carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM7022, HBM7008, HBM9027, HBM7004, and HB…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is HBM Holdings (HBMHF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.98 versus a price of $1.56 — about +27% (undervalued). Model-based estimate, not financial advice.
What is the fair value of HBMHF?
Our 21-model fair value for HBM Holdings is $1.98 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.56.
What is the quality score of HBMHF?
HBM Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.